stockrowPrestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.
- Revenue
- +22.7%
- EPS
- −38.4%
- Free cash flow
- −38.2%
- Total debt
- +100.9%
Quarter to September 2026, against a year earlier
Follow PBH
Alert me
Prestige Consumer Healthcare Inc. (PBH) Shares outstanding
Prestige Consumer Healthcare Inc.'s shares outstanding at the end of fiscal 2026 was $48.7M, unchanged from fiscal 2025. At the end of the quarter to 30 September 2026 it was $47.6M. Over the past ten years it has ranged from $48.7M (fiscal 2026) to $53.5M (fiscal 2018) — the current reading is the lowest in ten years. Prestige Consumer Healthcare Inc. ranks 43rd of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2026 | $48.7M | (2.72%) |
| FY2025 | $50.1M | (0.20%) |
| FY2024 | $50.2M | 0.58% |
| FY2023 | $49.9M | (1.87%) |
| FY2022 | $50.8M | 0.47% |
| FY2021 | $50.6M | (1.05%) |
| FY2020 | $51.1M | (1.78%) |
| FY2019 | $52.1M | (2.72%) |
| FY2018 | $53.5M | 0.31% |
| FY2017 | $53.4M | 0.41% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $47.6M | (0.02%) |
| Jun 2026 | $47.6M | (2.29%) |
| Mar 2026 | $48.7M | 1.32% |
| Dec 2025 | $48.1M | (2.39%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ALVO Alvotech compare | $295.0M |
| BCRX BioCryst Pharmaceuticals, Inc. compare | $267.6M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $214.3M |
| TRLV Trulieve Cannabis Corp. compare | $200.6M |
| XERS Xeris Biopharma Holdings, Inc. compare | $189.9M |
| PRGO Perrigo Company plc compare | $139.4M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | $111.2M |
| PBH Prestige Consumer Healthcare Inc. | $47.6M |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on PBH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement